FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/02/2026
Voltar para busca
Dado oficial do USPTO
SERB PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 10, 42, 44
Data de depósito
15/01/2024
Data de registro
15/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/07/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
LU
Examinador
DOMBROW, COLLEEN M
Unidade examinadora
L10
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the wording "SERB PHARMACEUTICALS" in the color purple. The word "SERB" appears above the word "PHARMACEUTICALS". To the left of the wording is a circular shape resembling a donut. Starting on the left side of the donut shape and moving clockwise, the left side and bottom of the donut shape is in the color light purple, above the light purple shading is dark purple, following by purple and finally followed by medium purple. The color white represents background only and is not claimed as a feature of the mark.
Titulares e representantes
Titulares
SERB
Representantes
Sherry L. Rollo Hahn Loeser & Parks, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparations for scientific useother than for medical or veterinary use; Chemical substances for scientific use for analyses in laboratoriesother than for medical or veterinary use; chemical preparations and substances with or without coloring agents for laboratory analysesother than for medical or veterinary use; chemical preparations for scientific purposes other than for medical or veterinary use; diagnostic preparations and substances in the nature of chemicals with or without coloring agents other than for medical or veterinary usechemical diagnostic reagents for industrial purposes; chemical additives with or without coloring agents used in the composition of diagnostic preparations and substanceschemical additives for use in the manufacture of pharmaceuticals; chemical reagents with or without coloring agentsother than for medical or veterinary usechemical reagents for non-medical purposes; active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of snake bite venomthe treatment of digoxin toxicity and overdosethe treatment of methotrexate toxicity and overdosethe treatment of exposure to nuclear radiation and the treatment of cyanide poisoning
Classe 5
Pharmaceutical preparationsmedicines and substancespharmaceutical preparations for treating poisoningsoverdoses of any typeallergiessnake bitesexposure to nuclear radiationinfectionstumorsheart diseasesblood diseasesskin diseasesgastric diseasesliver diseasesneurological diseasesophthalmological diseaseslung diseasesrheumatological diseasesrare ocular diseases; Pharmaceutical preparations for the treatment of snake bite venom; Pharmaceutical preparations for the treatment of digoxin toxicity and overdose; Pharmaceutical preparations for the treatment of methotrexate toxicity and overdose; Pharmaceutical preparationspotassium iodidefor the treatment of exposure to nuclear radiation; Pharmaceutical preparations for the treatment of cyanide poisoning; Antidotes; veterinary preparationsmedicines and substancesveterinary preparations of snake bite venom to treat snake bitesveterinary preparations for the treatment of digoxin toxicity and overdoseveterinary preparations for the treatment of methotrexate toxicity and overdoseveterinary preparations for the treatment of cyanide poisoning; Biological preparations for medicalpharmaceutical and veterinary usebiological preparations for the treatment of cancer; radioactive substances for medical use; dietetic beverages and foods adapted for medical use; nutritional supplements for medical use; diagnostic preparations for medical or veterinary use; chemical reagents for medical or veterinary use; radiological contrast substances for medical use; herbal tinctures for medical use; surgical implants made of living tissue; medical and veterinary microbial mediacell culture media for medical and veterinary use; cultures of microorganisms for medical or veterinary use; antibiotic preparations; dressings for medical use.
Classe 10
Surgical apparatus and instruments for medicaldental and veterinary use; infusion apparatus for therapeutic use; thermometers for medical use; Artificial implantsimplants consisting of artificial materials; stents; Dental prostheses; cardiac pacemakers; lenses in the nature of intraocular prostheses for surgical implantation; Orthopedic articlesorthopedic braces for the prevention and the correction of disorders of the musculoskeletal system affecting bonesjointsmusclestendons and nerves; x-ray apparatus for medical use; Electromagnetic medical diagnostic imaging apparatus; Medical diagnostic instruments for the analysis of body fluids; Medical diagnostic equipmentdiagnostic penlights for medical purposes
Classe 42
Medical research services; Scientific research for medical use; pharmaceutical diagnostic testing servicestesting of pharmaceuticals; pharmaceutical diagnostic testing servicesscientific research in the nature of conducting clinical trials for others in the field of pharmaceuticals; Research and development of new products; assessment in scientific and technical fields provided by engineersconsulting in the field of engineering; Appraisals in the fields of science and technology provided by engineersconducting scientific feasibility studies; scientific research; Technical and scientific studiesconducting scientific feasibility studies
Classe 44
Medical services; medical assistance; veterinary services; consultation with respect to pharmacypharmaceutical consultation
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/02/2026
FIMP
FINAL DISPOSITION PROCESSED
06/02/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/12/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/11/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
26/11/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
15/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
15/07/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/05/2025
PUBO
PUBLISHED FOR OPPOSITION
27/05/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/04/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
29/04/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
29/04/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
29/04/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/04/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/04/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
24/04/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/01/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/01/2025
GNFR
FINAL REFUSAL E-MAILED
03/01/2025
CNFR
FINAL REFUSAL WRITTEN
03/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/12/2024
RFNT
REFUSAL PROCESSED BY IB
09/09/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/08/2024
RFRR
REFUSAL PROCESSED BY MPU
20/08/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/08/2024
CNRT
NON-FINAL ACTION WRITTEN
12/08/2024
DOCK
ASSIGNED TO EXAMINER
09/08/2024
MAFR
APPLICATION FILING RECEIPT MAILED
01/07/2024
MAFR
APPLICATION FILING RECEIPT MAILED
28/06/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/06/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/06/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SERB PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.